A Phase 2 Trial of EPOCH (Etoposide, Vincristine, Doxorubicin, Cyclophophamide and Prednisolone) Chemotherapy for Previously Treated Non - Hodgkin's Lymphoma.
- Author:
Baek Yeol RYOO
;
Tae You KIM
;
Young Hyuk IM
;
Jhin Oh LEE
;
Taik Koo YUN
;
Keun Chil PARK
- Publication Type:Original Article
- Keywords:
Non-Hodgkin's lymphoma;
EPOCH(etoposide, vincristine, doxorubicin, cyclophosphamide, prednisolone) chemotherapy
- MeSH:
Cyclophosphamide;
Disease-Free Survival;
Doxorubicin*;
Drug Resistance;
Drug Therapy*;
Follow-Up Studies;
Hodgkin Disease*;
Humans;
Leukopenia;
Lymphoma, Non-Hodgkin;
Prednisolone;
Sepsis;
Stomatitis;
Vincristine*
- From:Journal of the Korean Cancer Association
1998;30(1):127-136
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: As a new strategy to modulate drug resistance in the treatment of relapsed or refractory non-Hodgkin's lymphoma(NHL), continuos infusion of drugs has been incorporated into the chemotherapy. We conducted a phase II study to determine the activity and safety of EPOCH (etoposide, vincristine, doxorubicin, cyclophosphamide, prednisolone) chemotherapy, in which the natursl products are administered as a continuous infusion, for previously treated NHL's of intermediate grade. MATERIALS AND METHODS: EPOCH chemotherapy (etoposide 50 mg/m2/day 24 hour- continuous infusion, days 1~4, vincristine 0.4 mg/m2/day 24 hour-continuous infusion, days 1~4, doxorubicin 10 mg/m2/day 24 hour-continuous infusion, days 1~4, cyclophosphamide 750 mg/m2 i.v., day 5, prednisolone 60 mg/m2/day p.o. days 1-5) was given to eligible patients every 3 weeks and we assessed response and toxicity of the regimen. RESULTS: Between June 1993 and December 1995, total 56 patients entered this trial and 49 were evaluable. The complete response rate was 41%(95% C.I.: 27-55%). After follow up of 9~50(median 38) months, progression free survival was 0~39+(median 7) months and the overall survival was 1~44+(median 14) months. The prognostic factor analyses showed that B symtoms and serum LDH level before treatment and response to previous treatment affected complete response rate, and patients' performance status and response to previous treatment affected progression free survival and overall survival. Toxicities of EPOCH regimen were leukopenia, stomatitis, nausea/vomiting and neurotoxicity, but they were tolerable. There was 1 case of treatment-related death due to sepsis. CONDUSION: EPOCH chemotherapy was safe and effective for the patients with relapsed NHL. However, the results of patients with NHL refractory to previous treatment were so poor that more intensive, novel treatment would be needed for this category of patients.
